Clinical TrialMay 18, 2026, 09:07 AM
MetaVia to Present 3 Late-Breaking Abstracts on Obesity Assets at ADA 2026
AI Summary
MetaVia Inc. announced that three late-breaking abstracts highlighting its cardiometabolic assets, DA-1726 and vanoglipel (DA-1241), have been accepted for poster presentations at the American Diabetes Association’s (ADA) 2026 Scientific Sessions. DA-1726 is a dual GLP-1/glucagon agonist for obesity, currently in a Phase 1 titration study with data expected in Q4 2026. Vanoglipel, a GPR119 agonist, showed broad therapeutic potential for liver and metabolic diseases. Two preclinical posters for vanoglipel explore combination therapies for metabolic dysfunction-associated steatohepatitis (MASH) and Type 2 diabetes.
Key Highlights
- MetaVia to present three late-breaking abstracts at the American Diabetes Association's (ADA) 2026 Scientific Sessions from June 5-8.
- Abstracts highlight cardiometabolic assets DA-1726 and vanoglipel (DA-1241).
- DA-1726 is a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for obesity.
- Vanoglipel (DA-1241) is a novel GPR119 agonist with therapeutic potential for MASH and Type 2 diabetes.
- One poster details Phase 1 higher-dose cohort results for DA-1726's safety, tolerability, pharmacokinetics, and pharmacodynamics.
- Two preclinical posters for vanoglipel explore combination therapies for MASH and Type 2 diabetes.
- Data from DA-1726's 16-week Phase 1 Part 3 titration study is expected in the fourth quarter of 2026.
Price Impact
More from MTVA